inclusion criteria: * patients age ≥ 18 years at screening * patients with mild or moderate c19 pneumonia, defined as grade 3 or 4 severity by the who covid-19 ordinal scale by * patients meeting criteria: hospitalization and sars-cov2 infection (clinically suspected\* or laboratory-confirmed) and radiological change consistent with covid-19 disease * c-reactive protein (crp) greater than or equal to 30mg/l * informed consent from patient or personal or professional representative * no medical history that might, in the opinion of the responsible clinician, put the patient at significant risk if he/she were to participate in the trial * agreement to abstain from sexual intercourse or use contraception that is \>99% effective for all participants of childbearing potential for 42 days after the last dose of study drug. for male participants, agreement to abstain from sperm donation for 42 days after the last dose of study drug. * able to read english. non-english speakers will be able to join the study. if patients are unable to understand verbal or written information in english - hospital translation services will be requested at the participating site for the participant where possible.

inclusion criteria: * patients age ≥ 18 years at screening * patients with mild or moderate c19 pneumonia, defined as grade 3 or 4 severity by the who covid-19 ordinal scale by * patients meeting criteria: hospitalization and sars-cov2 infection (clinically suspected\* or laboratory-confirmed) and radiological change consistent with covid-19 disease * c-reactive protein (crp) greater than or equal to 30mg/l * informed consent from patient or personal or professional representative * no medical history that might, in the opinion of the responsible clinician, put the patient at significant risk if he/she were to participate in the trial * agreement to abstain from sexual intercourse or use contraception that is \>99% effective for all participants of childbearing potential for 42 days after the last dose of study drug. for male participants, agreement to abstain from sperm donation for 42 days after the last dose of study drug. * able to read english. non-english speakers will be able to join the study. if patients are unable to understand verbal or written information in english - hospital translation services will be requested at the participating site for the participant where possible.

inclusion criteria: - patients age ≥ 18 years at screening - patients with mild or moderate c19 pneumonia, defined as grade 3 or 4 severity by the who covid-19 ordinal scale by - patients meeting criteria: hospitalization and sars-cov2 infection (clinically suspected* or laboratory-confirmed) and radiological change consistent with covid-19 disease - c-reactive protein (crp) greater than or equal to 30mg/l - informed consent from patient or personal or professional representative - no medical history that might, in the opinion of the responsible clinician, put the patient at significant risk if he/she were to participate in the trial - agreement to abstain from sexual intercourse or use contraception that is >99% effective for all participants of childbearing potential for 42 days after the last dose of study drug. for male participants, agreement to abstain from sperm donation for 42 days after the last dose of study drug. - able to read english. non-english speakers will be able to join the study. if patients are unable to understand verbal or written information in english - hospital translation services will be requested at the participating site for the participant where possible.

inclusion criteria: - patients age ≥ 18 years at screening - patients with mild or moderate c19 pneumonia, defined as grade 3 or 4 severity by the who covid-19 ordinal scale by - patients meeting criteria: hospitalization and sars-cov2 infection (clinically suspected* or laboratory-confirmed) and radiological change consistent with covid-19 disease - c-reactive protein (crp) greater than or equal to 30mg/l - informed consent from patient or personal or professional representative - no medical history that might, in the opinion of the responsible clinician, put the patient at significant risk if he/she were to participate in the trial - agreement to abstain from sexual intercourse or use contraception that is >99% effective for all participants of childbearing potential for 42 days after the last dose of study drug. for male participants, agreement to abstain from sperm donation for 42 days after the last dose of study drug. - able to read english. non-english speakers will be able to join the study. if patients are unable to understand verbal or written information in english - hospital translation services will be requested at the participating site for the participant where possible.

inclusion criteria: - patients age ≥ 18 years at screening - patients with mild or moderate c19 pneumonia, defined as grade 3 or 4 severity by the who covid-19 ordinal scale by - patients meeting criteria: hospitalization and sars-cov2 infection (clinically suspected* or laboratory confirmed) and radiological change consistent with covid-19 disease - c-reactive protein (crp) greater than or equal to 50mg/l - informed consent from patient or personal or professional representative - no medical history that might, in the opinion of the responsible clinician, put the patient at significant risk if he/she were to participate in the trial - agreement to abstain from sexual intercourse or use contraception that is >99% effective for all participants of childbearing potential for 42 days after the last dose of study drug. for male participants, agreement to abstain from sperm donation for 42 days after the last dose of study drug. - able to read english. non-english speakers will be able to join the study. if patients are unable to understand verbal or written information in english - hospital translation services will be requested at the participating site for the participant where possible.

inclusion criteria: - patients age ≥ 18 years at screening - patients with mild or moderate c19 pneumonia, defined as grade 3 or 4 severity by the who covid-19 ordinal scale by - patients meeting criteria: hospitalization and sars-cov2 infection (clinically suspected* or laboratory confirmed) and radiological change consistent with covid-19 disease - c-reactive protein (crp) greater than or equal to 50mg/l - informed consent from patient or personal or professional representative - no medical history that might, in the opinion of the responsible clinician, put the patient at significant risk if he/she were to participate in the trial - agreement to abstain from sexual intercourse or use contraception that is >99% effective for all participants of childbearing potential for 42 days after the last dose of study drug. for male participants, agreement to abstain from sperm donation for 42 days after the last dose of study drug. - able to read english. non-english speakers will be able to join the study. if patients are unable to understand verbal or written information in english - hospital translation services will be requested at the participating site for the participant where possible.